If you have been reading about Visceral adiposity and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
By the end of the 1960s, peptides were phased out as drug candidates. Miguel Ondetti moved to the gastrointestinal hormone group in the mid 1960s. The first hormone to be studied by Ondetti's group was cholecystokinin, a digestion hormone. This product presented unique challenges because of the small amounts used in reactions. Unfortunately, bioassays were not quantitative enough to use for results and chemical reactions did not run well as such low amounts.
== Side effects == The most common side effects reported with naltrexone are gastrointestinal complaints such as diarrhea and abdominal cramping. These adverse effects are analogous to the symptoms of opioid withdrawal, as the μ-opioid receptor blockade will increase gastrointestinal motility. The side effects of naltrexone by incidence are as follows:
== History == The first documented example of an aerogel was created by Samuel Stephens Kistler in 1931, as a result of a bet with Charles Learned over who could replace the liquid in "jellies" with gas without causing shrinkage.
=== United Kingdom === Public Health England reported that the total number of antibiotic resistant infections in England rose by 9% from 55,812 in 2017 to 60,788 in 2018, but antibiotic consumption had fallen by 9% from 20.0 to 18.2 defined daily doses per 1,000 inhabitants per day between 2014 and 2018.
Sources: en.wikipedia.org
== Production == Dynorphin is produced in many different parts of the nervous system, including the hypothalamus, the striatum, the hippocampus and the spinal cord. Gene expression patterns from the Allen Brain Atlases in mouse, macaque and humans can be seen here. Dynorphin has many different physiological actions, depending upon its site of production.
Thirdly, succinylcholine use has been associated with postoperative myalgia, where patients often experience muscle pain similar to that of post-exercise muscle pain mainly in the shoulders, neck, neck and upper abdominal muscle the following day after surgery, especially in young healthy patients with greater muscle mass, whereas reports from children, elderly and pregnant woman are less frequent. This is caused by the fasciculations (muscle twitches) that appear in sites such as intercostal muscles, and the diaphragm. These fasciculations are not relieved through analgesics, and in common practice, a sub-paralyzing dose of non-depolarizing neuromuscular blocker is administered a few minutes before succinylcholine administration to reduce visible fasciculation and postoperative myalgia. The use of succinylcholine is therefore also contraindicated in patient with muscle myopathy within 24 to 72 hours post-administration. Non-depolarizing drug Atracurium: Atracurium is commonly associated with histamine-related symptoms, most notably flushing and erythema. Less commonly seen adverse effects include urticaria, hypotension, wheezing, tachycardia, bronchospasm, dyspnea, bradycardia, and laryngospasm. Moreover, drops of up to 30 mmHg in mean arterial pressure was also observed within two minutes of administration in some patients. H1 and H2 receptor blocking agents can be used to attenuate the drop in mean arterial pressure. A slow injection speed between 30 and 60 seconds reduces adverse effects.
An intentional controlled detonation of illegal fireworks by the Los Angeles Police Department in a busy neighborhood of South Los Angeles does not go as planned, injuring seventeen people, including 10 LAPD officers, and damaging windows, cars, and buildings.
==== Reoxygenation of tolerant animals ==== Hypoxia/anoxia tolerant species handle ROS production during reoxygenation better than the intolerant. In the cortex of the naked mole rats, they show better homeostasis of ROS production than intolerant species and seem to lack the burst of ROS that typically comes with reoxygenation.
The Spanish navy had been totally dismantled by a disastrous naval policy and relegated to the background by the urgency of the war against Napoleon itself. To 1817, Tsar Alexander supported reactionary governments. Ferdinand VII applied to the Tsar to purchase vessels. The Tsar agreed to this request with the offer of the sale of some of his own vessels. The agreement was finally negotiated at Madrid, between Dmitry Tatishchev, Russian ambassador, and Eguia, Minister of war. It was apparently known only to these two, and to the king himself. The text of the treaty of sale has not been found in the Spanish naval archives. This diplomatic transaction was veiled in the deepest secrecy against Spanish Navy and Minister of Navy. The requested fleet would consist of 5 warships and 3 frigates. The squadron would be delivered to Cadiz, duly armed, and supplied. The arrival of the Russian fleet in Cadiz in February 1818 was not to the liking of the Spanish navy, which was dissatisfied with the state of deterioration in which some supposedly new ships were found: between 1820 and 1823 all the warships were scrapped as being useless. This fiasco put an end to the whole plan to reconquer the Rio de la Plata, which would end with the uprising of the Spanish Army in Cadiz (Trienio Liberal). In 1818 one of the frigates (Maria Isabel aka Patrikki) was captured in the Pacific, after the uprising of one of the Spanish troop transports that went over to the side of the American rebels delivering all the keys, routes and signals for the capture of the frigate.
Sources: en.wikipedia.org
The 1946 elections saw the Muslim League secure 90 percent of the Muslim seats, supported by the landowners of Sindh and Punjab. This forced the Indian National Congress, initially skeptical of the League's representation of Indian Muslims, to acknowledge its significance. Jinnah's emergence as the voice of the Indian Muslims, compelled the British to consider their stance, despite their reluctance to partition India. In a final attempt to prevent partition, they proposed the Cabinet Mission Plan. As the Cabinet Mission failed, the British announced their intention to end rule by June 1948. Following rigorous discussions involving Viceroy of India, Lord Mountbatten of Burma, Muhammad Ali Jinnah of the All-India Muslim League, and Jawaharlal Nehru of Congress, the formal declaration to partition British India into two independent dominions—namely Pakistan and India—was issued by Mountbatten on the evening of 3 June 1947. In Mountbatten's oval office, the prime ministers of around a dozen major princely states gathered to receive their copies of the plan before its worldwide broadcast. At 7:00 P.M., All India Radio transmitted the public announcement, starting with the viceroy's address, followed by individual speeches from Nehru, and Jinnah. The founder of Pakistan Muhammad Ali Jinnah concluded his address with the slogan Pakistan Zindabad (Long Live Pakistan).
== Medical uses == Lebrikizumab is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents aged twelve years of age and older with a body weight of at least 40 kilograms (88 lb) who are candidates for systemic therapy.
Combined with a better understanding of female pelvic floor connective tissue, these ideas would go on to influence surgical approaches for the treatment of uterine prolapse. By the early 20th century, different techniques for vaginal hysterectomies had been described and performed. As a result, post-hysterectomy vaginal vault prolapse became more common and a growing concern for some surgeons, and new techniques to correct this complication were attempted. In 1957, Arthure and Savage of London's Charing Cross Hospital, suspecting that uterine prolapse could not be cured with hysterectomy alone, published their surgical technique of sacral hysteropexy. Their technique is still used in modern practice with the addition of a graft.
It was not long before Maximilien de Robespierre and the now dominant Jacobin Club turned against the radical factions of the National Convention, including the sans-culottes, despite their having previously been the strongest supporters of the revolution and its government. Several important leaders of the Enragés and Hébertists were imprisoned and executed by the very revolutionary tribunals they had supported. The execution of radical leader Jacques Hébert spelled the decline of the sans-culottes, and with the successive rise of even more conservative governments, the Thermidorian Convention and the French Directory, they were definitively silenced as a political force. After the defeat of the 1795 popular revolt in Paris, the sans-culottes ceased to play any effective political role in France until the July Revolution of 1830.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.